M&A M&A
Cohance acquires 65% in US-based Aruka Bio for $5-M
Source Business Line (opens in a new tab)BSE Announcement (opens in a new tab)
Hyderabad-based Cohance Lifesciences (formerly known as Suven Pharmaceuticals) is to invest USD 5-M to acquire a 65% controlling stake in Aruka Bio , a Princeton, NJ (USA)-based biotechnology company that develops next-generation antibody-drug conjugate therapies.This move aims to position Aruka Bio to pursue collaborations and licensing with pharmaceutical partners.